Blair William & Co. IL Cuts Stock Position in Takeda Pharmaceutical Co. (NYSE:TAK)

Blair William & Co. IL decreased its holdings in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 12.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,623 shares of the company’s stock after selling 1,576 shares during the quarter. Blair William & Co. IL’s holdings in Takeda Pharmaceutical were worth $158,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. FNY Investment Advisers LLC acquired a new position in Takeda Pharmaceutical in the 1st quarter worth $37,000. Farther Finance Advisors LLC increased its position in shares of Takeda Pharmaceutical by 29.2% during the first quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company’s stock worth $69,000 after acquiring an additional 1,045 shares during the last quarter. Fifth Third Bancorp lifted its stake in shares of Takeda Pharmaceutical by 85.5% in the first quarter. Fifth Third Bancorp now owns 5,232 shares of the company’s stock worth $78,000 after acquiring an additional 2,411 shares in the last quarter. Point72 Hong Kong Ltd purchased a new position in Takeda Pharmaceutical in the fourth quarter valued at about $94,000. Finally, GAMMA Investing LLC grew its stake in Takeda Pharmaceutical by 22.6% during the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company’s stock valued at $105,000 after purchasing an additional 1,296 shares in the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Price Performance

TAK stock opened at $14.76 on Thursday. The stock’s 50 day moving average is $14.79 and its two-hundred day moving average is $14.59. Takeda Pharmaceutical Co. has a 52-week low of $12.80 and a 52-week high of $15.53. The company has a market capitalization of $46.97 billion, a PE ratio of 49.20 and a beta of 0.22. The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. The business had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. Analysts predict that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.